J.P. Morgan Downgrades Essity AB on Rising Costs and Weak Earnings Outlook 
Indonesia and Toyota Explore $300M Bioethanol Investment to Boost Renewable Energy Goals 
Daikin Industries Stock Surges 14% After Elliott Investment Management Discloses Major Stake 
NiSource Signs Long-Term Energy Deals with Alphabet and Amazon to Power Indiana Data Centers 
TSMC Posts Record Q1 Profit Fueled by AI Chip Demand 
Greg Abel Sells Berkshire Hathaway Stocks Managed by Former Investment Manager Todd Combs 
SK Hynix Launches 192GB SOCAMM2 Memory for Nvidia’s Next-Gen AI Chips 
Australia Extends Fuel Sulphur Relaxation Amid Iran War Supply Disruptions 
Apple Wins ITC Ruling, Keeping Blood-Oxygen Feature on Apple Watch 
China Food Delivery Stocks Dip as Regulators Crack Down on “Ghost Deliveries” 
AEVEX Raises $320 Million in IPO Amid Surging Defense Sector Demand 
JAPEX Shares Drop as Middle East Tensions Drive LNG Costs and Production Risks 
How Technology Is Reshaping Modern Business: From Operations to Customer Experience 
Elon Musk Faces French Probe Over X and Grok Amid Rising U.S.-EU Tensions 
Japan to Subsidize Sony's Image Sensor Plant in Kumamoto with $380 Million 
CATL Stock Hits Record High After Q1 2025 Earnings Surge 
NVIDIA Acquisition Rumors Dismissed by Morgan Stanley as Strategically Flawed 
SEATTLE, Feb. 24, 2017 -- NanoString Technologies, Inc. (NASDAQ:NSTG), a provider of life science tools for translational research and molecular diagnostic products, today announced that the Company will release fourth quarter and fiscal year 2016 financial results after the close of trading on Wednesday, March 1, 2017. Company management will host a conference call beginning at 4:30pm ET to discuss those results and provide a business update.
Individuals interested in listening to the conference call may do so by dialing (888) 793-9492 for domestic callers, or (734) 385-2643 for international callers. Please reference Conference ID: 49371012. To listen to a live webcast, please visit the investor relations section of the company’s website at nanostring.com.
A replay of the call will be available beginning March 1, 2017 at 7:30pm ET through midnight on March 8, 2017. To access the replay, dial (855) 859-2056 or (404) 537-3406 and reference Conference ID: 49371012. The webcast will also be available on the Company’s website for one year following the completion of the call.
About NanoString Technologies, Inc.
NanoString Technologies provides life science tools for translational research and molecular diagnostic products. The company's nCounter Analysis System has been employed in life sciences research since it was first introduced in 2008 and has been cited in more than 1,500 peer-reviewed publications. The nCounter Analysis System offers a cost-effective way to easily profile the expression of hundreds of genes, proteins, miRNAs, or copy number variations, simultaneously with high sensitivity and precision, facilitating a wide variety of basic research and translational medicine applications, including biomarker discovery and validation. The company's technology is also being used in diagnostics. The Prosigna® Breast Cancer Prognostic Gene Signature Assay together with the nCounter Dx Analysis System is FDA 510(k) cleared for use as a prognostic indicator for distant recurrence of breast cancer. In addition, the company is collaborating with multiple biopharmaceutical companies in the development of companion diagnostic tests for various cancer therapies, helping to realize the promise of precision oncology. For more information, please visit www.nanostring.com.
Contact: Doug Farrell Vice President, Investor Relations & Corporate Communications [email protected] Phone: 206-602-1768
